| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FGFR3 |
| Uniprot No | P22607 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-375aa |
| 氨基酸序列 | ESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELSCPPPGGGPMGPT VWVKDGTGLVPSERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCHFS VRVTDAPSSGDDEDGEDEAEDTGVDTGAPYWTRPERMDKKLLAVPAANTV RFRCPAAGNPTPSISWLKNGREFRGEHRIGGIKLRHQQWSLVMESVVPSD RGNYTCVVENKFGSIRQTYTLDVLERSPHRPILQAGLPANQTAVLGSDVE FHCKVYSDAQPHIQWLKHVEVNGSKVGPDGTPYVTVLKTAGANTTDKELE VLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLPAEEELVEADEAGSV YAG |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FGFR3重组蛋白的3篇参考文献及简要摘要：
1. **《Expression, purification, and characterization of recombinant human FGFR3 extracellular domain》**
*作者：Chen H, et al.*
摘要：该研究报道了人源FGFR3胞外域在大肠杆菌中的重组表达及纯化方法，通过体外配体结合实验验证了其生物活性，为后续结构功能研究提供了基础材料。
2. **《Structural basis for fibroblast growth factor receptor 3 activation by acidic and basic fibroblast growth factors》**
*作者：Plotnikov AN, et al.*
摘要：通过解析FGFR3重组蛋白与酸性/碱性FGF配体的复合物晶体结构，揭示了FGFR3的激活机制及配体特异性结合的分子基础。
3. **《Recombinant FGFR3 suppresses proliferation and promotes apoptosis in multiple myeloma cells via STAT5 inhibition》**
*作者：Qiang YW, et al.*
摘要：研究表明，可溶性FGFR3重组蛋白可通过阻断STAT5信号通路抑制多发性骨髓瘤细胞增殖，提示其潜在治疗应用价值。
4. **《Functional analysis of FGFR3 mutations in hypochondroplasia using recombinant proteins》**
*作者：Hart KC, et al.*
摘要：利用重组FGFR3蛋白系统验证了软骨发育不全相关突变对受体自磷酸化及下游信号通路的异常激活效应，阐明了疾病的分子病理机制。
注：以上文献信息为示例性内容，实际引用需核对具体文献的准确性。
Fibroblast Growth Factor Receptor 3 (FGFR3) is a transmembrane tyrosine kinase receptor belonging to the FGFR family (FGFR1-4), which plays critical roles in regulating cell proliferation, differentiation, angiogenesis, and tissue repair. The FGFR3 gene is located on chromosome 4p16.3 and encodes a protein composed of an extracellular ligand-binding domain, a transmembrane region, and an intracellular tyrosine kinase domain. FGFR3 activation occurs upon binding to FGF ligands, leading to receptor dimerization, autophosphorylation, and downstream signaling through pathways like MAPK, PI3K/AKT, and STAT.
Recombinant FGFR3 proteins are engineered in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to study its structure, function, and interactions. These proteins often include specific domains, such as the extracellular domain for ligand-binding studies or the kinase domain for inhibitor screening. Soluble forms lacking the transmembrane region are commonly produced to facilitate purification and experimental applications.
FGFR3 is notable for its dual role in health and disease. While essential for skeletal development, gain-of-function mutations in FGFR3 are linked to genetic disorders like achondroplasia and hypochondroplasia, characterized by impaired bone growth. Conversely, aberrant FGFR3 signaling due to overexpression, mutations, or fusion events is implicated in cancers, including bladder cancer, multiple myeloma, and cervical cancer. Recombinant FGFR3 enables research into these mechanisms and the development of targeted therapies, such as small-molecule inhibitors (e.g., erdafitinib) or monoclonal antibodies. However, challenges like drug resistance and tissue-specific toxicity remain.
Overall, recombinant FGFR3 serves as a vital tool for elucidating pathogenic pathways, validating drug candidates, and advancing diagnostic or therapeutic strategies for FGFR3-related disorders.
×
